Henipavirus

EQS-News: Evotec receives grant from Open Philanthropy for discovery of RNA-targeting Henipavirus therapeutics

Retrieved on: 
Friday, June 2, 2023
Vaccine, Human, Therapy, Hendra virus, Nipah virus, Frankfurt Stock Exchange, Global health, Research, RNA, Hendra, Open Philanthropy (organization), Henipavirus, ISIN, World Health Organization, R, EVO

Evotec SE (Frankfurt Stock Exchange: EVT, ISIN: DE0005664809; NASDAQ: EVO) today announced that the Company has received a $ 1.7 m grant from Open Philanthropy, a philanthropic funder prioritising global health and wellbeing.

Key Points: 
  • Evotec SE (Frankfurt Stock Exchange: EVT, ISIN: DE0005664809; NASDAQ: EVO) today announced that the Company has received a $ 1.7 m grant from Open Philanthropy, a philanthropic funder prioritising global health and wellbeing.
  • Under the grant, Evotec aims to discover and develop RNA-targeting small molecules as potential first-in-class therapeutics against Henipaviruses.
  • The genus comprises six different established species including Hendra virus and Nipah virus, from which it receives its name.
  • This is the first time that we have been supported by Open Philanthropy and we are very excited about this opportunity.

Pandemic Antiviral Discovery (PAD) makes first investments to support the development of new antiviral medicines for future pandemics

Retrieved on: 
Thursday, February 23, 2023
Discovery, Hendra virus, Fatality, Pandemic, Bill, Senior, Nipah virus, Disease, Henipavirus, Drug development, National Center for Advancing Translational Sciences, Virus, Drug discovery, Research, Nipa, Investment, Novo Nordisk Foundation, PAD, Human, RFP, Bill & Melinda Gates Foundation, Infection, COVID-19, Open Philanthropy (organization), Vaccine, Pharmaceutical industry

COPENHAGEN, Denmark, Feb. 23, 2023 /PRNewswire/ -- Today, the partners in Pandemic Antiviral Discovery (PAD) initiative announced grants totalling more than USD 26 million for 14 research projects aimed at facilitating early-stage development of drugs to treat henipavirus infection and disease in humans.

Key Points: 
  • Its purpose is to accelerate the discovery and development of antiviral drugs for future pandemic threats.
  • With equitable access as a core principle of the initiative, PAD is focused on ensuring these interventions are accessible to people in low- and middle-income countries.
  • "Preparing for future pandemics means investing in the discovery of lifesaving interventions before viruses of concern escalate into deadly pandemics and ensuring those tools will be readily available to anyone who needs them."
  • To pave the way for the development of such antiviral drugs, greater knowledge of the henipavirus subfamily is needed.

Pandemic Antiviral Discovery (PAD) makes first investments to support the development of new antiviral medicines for future pandemics

Retrieved on: 
Thursday, February 23, 2023
Discovery, Hendra virus, Fatality, Pandemic, Bill, Senior, Nipah virus, Disease, Henipavirus, Drug development, National Center for Advancing Translational Sciences, Virus, Drug discovery, Research, Nipa, Investment, Novo Nordisk Foundation, PAD, Human, RFP, Bill & Melinda Gates Foundation, Infection, COVID-19, Open Philanthropy (organization), Vaccine, Pharmaceutical industry

COPENHAGEN, Denmark, Feb. 23, 2023 /PRNewswire/ -- Today, the partners in Pandemic Antiviral Discovery (PAD) initiative announced grants totalling more than USD 26 million for 14 research projects aimed at facilitating early-stage development of drugs to treat henipavirus infection and disease in humans.

Key Points: 
  • Its purpose is to accelerate the discovery and development of antiviral drugs for future pandemic threats.
  • With equitable access as a core principle of the initiative, PAD is focused on ensuring these interventions are accessible to people in low- and middle-income countries.
  • "Preparing for future pandemics means investing in the discovery of lifesaving interventions before viruses of concern escalate into deadly pandemics and ensuring those tools will be readily available to anyone who needs them."
  • To pave the way for the development of such antiviral drugs, greater knowledge of the henipavirus subfamily is needed.

Antech aligns with global health organizations on COVID-19 in cats and dogs: No virus detected

Retrieved on: 
Thursday, March 19, 2020
Viruses, Branches of biology, Zoonoses, Biology, Animal virology, Severe acute respiratory syndrome-related coronavirus, Polymerase chain reaction, Veterinary medicine, Severe acute respiratory syndrome, Henipavirus

Antech's active surveillance program is intended to detect any possible emergence of the virus among companion animals.

Key Points: 
  • Antech's active surveillance program is intended to detect any possible emergence of the virus among companion animals.
  • Antech's surveillance program involves testing samples from dogs and cats that are submitted for respiratory PCR analysis.
  • Antech is validating samples to ensure there is no evidence of the SARS-CoV-2 virus in the companion animals tested.
  • Today, Antech is driving the future of pet health as part of Mars Veterinary Health, a family-owned company focused on veterinary care.